New drug SPN-810 tested for kids with ADHD and severe behavior issues

NCT ID NCT00626236

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested four different doses of SPN-810 (molindone) in 78 children aged 6 to 12 with ADHD and serious conduct problems. The main goal was to see if the drug is safe and tolerable. Researchers measured behavior changes using a special rating scale. The trial is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPN-810 (molindone)
What this could lead to: If successful, this could point toward a new treatment option for children with ADHD who also have severe conduct problems.
What could go wrong: This was a small, early-phase trial (phase 2) with only 78 children. It focused on safety and tolerability, not on proving the drug works. The results may not apply to all children, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder conduct disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY CONDUCT DISORDER

Contacts and locations

Locations

Alliance Research Group

Richmond, Virginia, 23229, United States
CNS Healthcare

Orlando, Florida, 32806, United States
Capstone Clinical Research

Libertyville, Illinois, 60048, United States
Clinical Neuroscience Solutions, Inc.

Memphis, Tennessee, 38119, United States
Florida Clinical Research Center

Bradenton, Florida, 32408, United States
IPS Research

Oklahoma City, Oklahoma, 73103, United States
Northwest Clinical Trials

Bellevue, Washington, 98004, United States
Sarkis Clinical Trials

Gainesville, Florida, 32607, United States
The Psychopharm Research Cntr - LSU Dept of Psychiatry

Shreveport, Louisiana, 71103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.